Trials / Completed
CompletedNCT02296320
Study of the Efficacy and Safety of MEDI4893
A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 213 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI4893 | Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study. |
| OTHER | Placebo | Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study. |
Timeline
- Start date
- 2014-10-10
- Primary completion
- 2018-10-02
- Completion
- 2018-10-02
- First posted
- 2014-11-20
- Last updated
- 2019-12-23
- Results posted
- 2019-10-25
Locations
49 sites across 10 countries: United States, Belgium, Czechia, France, Germany, Greece, Hungary, Portugal, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02296320. Inclusion in this directory is not an endorsement.